See more : Dollar Tree, Inc. (0IC8.L) Income Statement Analysis – Financial Results
Complete financial analysis of CONMED Corporation (CNMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CONMED Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- BZAM Ltd. (Z6A.F) Income Statement Analysis – Financial Results
- Quetta Acquisition Corporation Common Stock (QETA) Income Statement Analysis – Financial Results
- Shede Spirits Co., Ltd. (600702.SS) Income Statement Analysis – Financial Results
- Flower One Holdings Inc. (FONE.CN) Income Statement Analysis – Financial Results
- DevMar Equities, Inc. (DEVM) Income Statement Analysis – Financial Results
CONMED Corporation (CNMD)
About CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.24B | 1.05B | 1.01B | 862.46M | 955.10M | 859.63M | 796.39M | 763.52M | 719.17M | 734.47M | 756.76M | 767.14M | 725.08M | 713.72M | 694.74M | 742.18M | 694.29M | 646.81M | 617.31M | 558.39M | 497.13M | 453.06M | 428.72M | 392.23M | 372.60M | 336.40M | 138.30M | 125.60M | 99.60M | 71.10M | 53.60M | 42.60M | 38.50M | 31.40M | 19.90M | 14.20M | 12.50M | 10.50M |
| Cost of Revenue | 568.50M | 474.23M | 442.60M | 402.16M | 430.38M | 390.52M | 365.35M | 355.19M | 337.47M | 336.00M | 350.29M | 361.30M | 350.14M | 348.34M | 357.41M | 359.80M | 345.16M | 333.97M | 304.28M | 271.50M | 237.43M | 215.89M | 204.37M | 158.74M | 152.80M | 146.00M | 67.20M | 59.00M | 47.40M | 34.90M | 26.90M | 20.30M | 18.40M | 15.30M | 11.70M | 7.50M | 6.40M | 5.50M |
| Gross Profit | 676.25M | 571.25M | 568.04M | 460.30M | 524.72M | 469.11M | 431.04M | 408.33M | 381.70M | 398.47M | 406.47M | 405.84M | 374.93M | 365.38M | 337.33M | 382.38M | 349.13M | 312.85M | 313.02M | 286.89M | 259.70M | 237.17M | 224.35M | 233.49M | 219.80M | 190.40M | 71.10M | 66.60M | 52.20M | 36.20M | 26.70M | 22.30M | 20.10M | 16.10M | 8.20M | 6.70M | 6.10M | 5.00M |
| Gross Profit Ratio | 54.33% | 54.64% | 56.21% | 53.37% | 54.94% | 54.57% | 54.12% | 53.48% | 53.08% | 54.25% | 53.71% | 52.90% | 51.71% | 51.19% | 48.56% | 51.52% | 50.29% | 48.37% | 50.71% | 51.38% | 52.24% | 52.35% | 52.33% | 59.53% | 58.99% | 56.60% | 51.41% | 53.03% | 52.41% | 50.91% | 49.81% | 52.35% | 52.21% | 51.27% | 41.21% | 47.18% | 48.80% | 47.62% |
| Research & Development | 52.60M | 47.15M | 43.57M | 40.47M | 45.46M | 42.19M | 32.31M | 32.25M | 27.44M | 27.78M | 25.83M | 28.21M | 28.65M | 29.65M | 31.84M | 33.11M | 30.40M | 30.72M | 25.47M | 20.21M | 17.31M | 16.09M | 14.83M | 14.87M | 12.10M | 12.00M | 3.00M | 3.00M | 2.80M | 2.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 400.14M | 355.62M | 351.80M | 338.40M | 303.09M | 293.94M | 310.73M | 302.47M | 277.71M | 276.46M | 266.31M | 272.44M | 240.54M | 234.83M | 216.69M | 183.18M | 157.45M | 141.74M | 140.56M | 124.67M | 107.20M | 93.60M | 35.30M | 31.60M | 25.60M | 21.00M | 25.30M | 14.30M | 11.90M | 10.10M | 6.90M | 5.00M | 3.90M | 3.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 504.71M | 454.04M | 414.75M | 373.82M | 400.14M | 355.62M | 351.80M | 338.40M | 303.09M | 293.94M | 310.73M | 302.47M | 277.71M | 276.46M | 266.31M | 272.44M | 240.54M | 234.83M | 216.69M | 183.18M | 157.45M | 141.74M | 140.56M | 124.67M | 107.20M | 93.60M | 35.30M | 31.60M | 25.60M | 21.00M | 25.30M | 14.30M | 11.90M | 10.10M | 6.90M | 5.00M | 3.90M | 3.30M |
| Other Expenses | 0.00 | -112.01M | -1.13M | -355.00K | -5.19M | 0.00 | 0.00 | -2.94M | 0.00 | 7.32M | 8.75M | 7.20M | 0.00 | 2.18M | 10.92M | 1.58M | -4.63M | 51.90M | 7.12M | 20.34M | -2.92M | 0.00 | 0.00 | 29.49M | 25.70M | 23.60M | 7.00M | 6.40M | 0.00 | 3.90M | 3.30M | 2.20M | 2.10M | 1.60M | 1.00M | 600.00K | 400.00K | 300.00K |
| Operating Expenses | 555.64M | 501.19M | 458.32M | 414.29M | 445.60M | 397.81M | 384.11M | 370.65M | 330.53M | 345.68M | 349.96M | 340.63M | 306.36M | 308.29M | 309.06M | 307.12M | 266.31M | 317.45M | 249.27M | 223.73M | 171.84M | 157.82M | 155.39M | 169.03M | 145.00M | 129.20M | 45.30M | 41.00M | 33.40M | 27.30M | 28.60M | 16.50M | 14.00M | 11.70M | 7.90M | 5.60M | 4.30M | 3.60M |
| Cost & Expenses | 1.12B | 975.42M | 900.92M | 816.45M | 875.98M | 788.33M | 749.46M | 725.84M | 667.99M | 681.68M | 700.25M | 701.93M | 656.50M | 656.63M | 666.47M | 666.92M | 611.48M | 651.42M | 553.56M | 495.23M | 409.28M | 373.71M | 359.76M | 327.77M | 297.80M | 275.20M | 112.50M | 100.00M | 80.80M | 62.20M | 55.50M | 36.80M | 32.40M | 27.00M | 19.60M | 13.10M | 10.70M | 9.10M |
| Interest Income | 0.00 | 28.91M | 35.49M | 44.05M | 42.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 39.78M | 28.91M | 35.49M | 44.05M | 42.70M | 20.65M | 18.20M | 15.36M | 6.03M | 6.11M | 5.61M | 5.73M | 6.68M | 7.11M | 7.09M | 10.37M | 16.23M | 19.12M | 15.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 51.40M | 49.76M | 49.79M | 52.24M | 50.99M | 61.80M | 58.55M | 55.31M | 43.88M | 45.73M | 47.87M | 46.62M | 42.69M | 41.81M | 41.28M | 32.34M | 31.53M | 29.85M | 30.79M | 26.87M | 24.85M | 22.37M | 30.15M | 29.49M | 25.70M | 23.60M | 7.00M | 6.40M | 5.00M | 3.90M | 3.30M | 2.20M | 2.10M | 1.60M | 1.00M | 600.00K | 400.00K | 300.00K |
| EBITDA | 192.48M | 7.80M | 158.38M | 113.58M | 124.91M | 133.11M | 105.48M | 90.04M | 95.05M | 98.52M | 104.11M | 111.83M | 47.06M | 94.58M | 66.52M | 111.97M | 112.53M | 25.25M | 94.53M | 89.20M | 112.71M | 101.72M | 99.11M | 93.95M | 100.50M | 84.80M | 32.80M | 32.00M | 23.80M | 12.80M | 1.40M | 8.00M | 8.20M | 6.00M | 1.30M | 1.70M | 2.20M | 1.70M |
| EBITDA Ratio | 15.46% | -4.01% | 10.74% | 5.29% | 7.74% | 8.29% | 5.89% | 11.79% | 13.22% | 13.41% | 13.79% | 14.58% | 15.34% | 13.86% | 10.01% | 14.50% | 16.07% | 12.03% | 16.47% | 19.91% | 25.30% | 22.45% | 23.12% | 23.95% | 26.97% | 25.21% | 50.04% | 25.48% | 23.90% | 18.00% | 2.99% | 18.08% | 20.52% | 19.11% | 6.03% | 10.56% | 16.80% | 16.19% |
| Operating Income | 130.79M | 70.05M | 37.85M | -26.97M | 1.60M | 71.31M | 46.94M | 37.68M | 51.18M | 52.79M | 56.51M | 65.21M | 8.27M | 57.09M | 28.27M | 75.26M | 80.99M | -4.60M | 63.75M | 63.16M | 79.96M | 79.35M | 68.96M | 64.46M | 74.80M | 61.20M | 25.80M | 25.60M | 18.80M | 8.90M | -1.90M | 5.80M | 6.10M | 4.40M | 300.00K | 1.10M | 1.80M | 1.40M |
| Operating Income Ratio | 10.51% | 6.70% | 3.74% | -3.13% | 0.17% | 8.29% | 5.89% | 4.93% | 7.12% | 7.19% | 7.47% | 8.50% | 1.14% | 8.00% | 4.07% | 10.14% | 11.67% | -0.71% | 10.33% | 11.31% | 16.08% | 17.51% | 16.08% | 16.44% | 20.08% | 18.19% | 18.66% | 20.38% | 18.88% | 12.52% | -3.54% | 13.62% | 15.84% | 14.01% | 1.51% | 7.75% | 14.40% | 13.33% |
| Total Other Income/Expenses | -49.96M | -140.92M | -36.61M | -44.41M | -47.89M | -20.65M | -18.20M | -18.30M | -6.03M | -6.11M | -5.88M | -5.73M | -59.40M | -11.44M | -10.11M | -6.00M | -13.43M | -19.80M | -15.58M | -13.60M | -26.95M | -25.99M | -30.82M | -34.29M | -32.30M | -30.90M | -36.50M | -100.00K | -2.00M | -600.00K | -200.00K | 300.00K | -200.00K | -700.00K | -100.00K | 100.00K | 0.00 | -200.00K |
| Income Before Tax | 80.83M | -70.86M | 73.11M | 1.60M | 31.23M | 50.65M | 28.73M | 19.38M | 45.14M | 46.68M | 50.63M | 59.48M | -2.31M | 45.66M | 18.16M | 69.26M | 64.76M | -24.40M | 48.17M | 49.56M | 53.01M | 54.84M | 38.13M | 30.18M | 42.50M | 30.30M | -10.70M | 25.50M | 16.80M | 8.30M | -2.10M | 6.10M | 5.90M | 3.70M | 200.00K | 1.20M | 1.80M | 1.20M |
| Income Before Tax Ratio | 6.49% | -6.78% | 7.23% | 0.19% | 3.27% | 5.89% | 3.61% | 2.54% | 6.28% | 6.35% | 6.69% | 7.75% | -0.32% | 6.40% | 2.61% | 9.33% | 9.33% | -3.77% | 7.80% | 8.88% | 10.66% | 12.10% | 8.89% | 7.69% | 11.41% | 9.01% | -7.74% | 20.30% | 16.87% | 11.67% | -3.92% | 14.32% | 15.32% | 11.78% | 1.01% | 8.45% | 14.40% | 11.43% |
| Income Tax Expense | 16.37M | 9.72M | 10.56M | -7.91M | 2.61M | 9.80M | -26.76M | 4.71M | 14.65M | 14.48M | 14.69M | 19.00M | -3.06M | 15.31M | 6.02M | 24.70M | 23.30M | -11.89M | 16.18M | 16.10M | 20.93M | 19.74M | 13.73M | 10.86M | 15.30M | 10.90M | -3.60M | 9.20M | 5.90M | 2.90M | -700.00K | 2.00M | 2.00M | 1.30M | 100.00K | 400.00K | 700.00K | 500.00K |
| Net Income | 64.46M | -80.58M | 62.54M | 9.52M | 28.62M | 40.85M | 55.49M | 14.66M | 30.50M | 32.19M | 35.94M | 40.48M | 752.00K | 30.35M | 12.14M | 44.56M | 41.46M | -12.51M | 31.99M | 33.47M | 32.08M | 34.15M | 24.41M | 19.31M | 27.20M | 17.80M | -7.10M | 16.30M | 10.90M | 5.40M | -1.40M | 4.10M | 3.90M | 2.40M | -300.00K | 800.00K | 1.10M | 700.00K |
| Net Income Ratio | 5.18% | -7.71% | 6.19% | 1.10% | 3.00% | 4.75% | 6.97% | 1.92% | 4.24% | 4.38% | 4.75% | 5.28% | 0.10% | 4.25% | 1.75% | 6.00% | 5.97% | -1.93% | 5.18% | 5.99% | 6.45% | 7.54% | 5.69% | 4.92% | 7.30% | 5.29% | -5.13% | 12.98% | 10.94% | 7.59% | -2.61% | 9.62% | 10.13% | 7.64% | -1.51% | 5.63% | 8.80% | 6.67% |
| EPS | 2.10 | -2.68 | 2.14 | 0.33 | 1.01 | 1.45 | 1.99 | 0.53 | 1.10 | 1.17 | 1.30 | 1.43 | 0.03 | 1.06 | 0.42 | 1.55 | 1.46 | -0.45 | 1.09 | 1.13 | 1.11 | 1.25 | 1.02 | 0.84 | 1.19 | 0.79 | -0.31 | 0.77 | 0.64 | 0.40 | -0.11 | 0.28 | 0.31 | 0.25 | -0.03 | 0.08 | 0.14 | 0.10 |
| EPS Diluted | 2.04 | -2.68 | 1.94 | 0.32 | 0.97 | 1.41 | 1.97 | 0.52 | 1.09 | 1.16 | 1.28 | 1.41 | 0.03 | 1.05 | 0.42 | 1.52 | 1.43 | -0.45 | 1.08 | 1.11 | 1.10 | 1.23 | 1.00 | 0.83 | 1.17 | 0.77 | -0.31 | 0.75 | 0.63 | 0.37 | -0.11 | 0.28 | 0.31 | 0.25 | -0.03 | 0.08 | 0.14 | 0.10 |
| Weighted Avg Shares Out | 30.67M | 30.04M | 29.16M | 28.58M | 28.33M | 28.12M | 27.94M | 27.80M | 27.65M | 27.40M | 27.72M | 28.30M | 28.25M | 28.72M | 29.07M | 28.80M | 28.39M | 27.79M | 29.35M | 29.62M | 28.90M | 27.32M | 23.93M | 22.99M | 22.91M | 22.63M | 22.65M | 21.07M | 17.04M | 13.49M | 13.12M | 14.64M | 12.71M | 9.72M | 11.24M | 10.00M | 7.85M | 7.00M |
| Weighted Avg Shares Out (Dil) | 31.55M | 30.04M | 32.22M | 29.46M | 29.50M | 28.89M | 28.17M | 27.96M | 27.86M | 27.77M | 28.11M | 28.65M | 28.63M | 28.91M | 29.14M | 29.23M | 28.99M | 27.79M | 29.62M | 30.15M | 29.17M | 27.77M | 24.41M | 23.27M | 23.17M | 23.02M | 22.65M | 21.82M | 17.42M | 14.46M | 13.12M | 14.64M | 12.71M | 9.72M | 11.24M | 10.00M | 7.85M | 7.00M |
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Here's Why Conmed (CNMD) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Conmed (CNMD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CONMED Corporation to Participate in a Fireside Chat at the Piper Sandler Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, President and Chief Executive Officer, Todd W. Garner, Executive Vice President and Chief Financial Officer, and Pat J. Beyer, Chief Operating Officer, will participate in a fireside chat...
Conmed (CNMD) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Conmed (CNMD) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Conmed (CNMD) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View
CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.
CONMED Corporation (CNMD) Q3 2024 Earnings Call Transcript
CONMED Corporation (NYSE:CNMD ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Curt Hartman – Chairman, President and Chief Executive Officer Pat Beyer – Chief Operating Officer Todd Garner – Executive Vice President and Chief...
Conmed (CNMD) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Source: https://incomestatements.info
Category: Stock Reports